JPMorgan raised the firm’s price target on Edwards Lifesciences (EW) to $85 from $80 and keeps a Neutral rating on the shares. The company reported better than expected Q2 results which will help bring confidence in its growth over the back half of the year, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating
- Edwards Lifesciences price target raised to $90 from $83 at Piper Sandler
- Edwards Lifesciences Announces Leadership Change in TAVR Division
- Strong Growth Potential for Edwards Lifesciences: Buy Rating Affirmed by Analyst Brandon Vazquez
- Edwards Lifesciences Reports Strong Q2 Growth